Quarterly Financial Releases, Upcoming Investor Conferences, and R&D Agreements - Research Report on Varian, DexCom, Zeltiq,

     Quarterly Financial Releases, Upcoming Investor Conferences, and R&D
  Agreements - Research Report on Varian, DexCom, Zeltiq, Globus, and Abaxis

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, November 6, 2013

NEW YORK, November 6, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Varian
Medical Systems, Inc. (NYSE: VAR), DexCom, Inc. (NASDAQ: DXCM), Zeltiq
Aesthetics, Inc. (NASDAQ: ZLTQ), Globus Medical, Inc. (NYSE: GMED), and
Abaxis, Inc. (NASDAQ: ABAX). Today's readers may access these reports free of
charge - including full price targets, industry analysis and analyst ratings -
via the links below.

Varian Medical Systems, Inc. Research Report

On October 23, 2013, Varian Medical Systems, Inc. (Varian) reported its Q4 FY
2013 and full-year FY 2013 (period ended September 30, 2013) financial
results. In Q4 FY 2013, the Company's revenues totaled $769.9 million, up 1.8%
YoY. During the quarter, net earnings stood at $117.3 million or $1.08 per
diluted share, compared with$120.2 million or $1.08 per diluted share in Q4 FY
2012. For full-year FY 2013, revenues came in at $2.9 billion, up 4.8% YoY.
Full year net earnings were reported at $438.2 million or $3.98 per diluted
share, compared with $427.0 million or $3.76 per diluted share in FY 2012. Dow
R. Wilson, President and CEO of Varian said, "Our X-Ray Products business
delivered a record performance with robust growth in orders for its tubes and
panels for filmless imaging. We are confident in the long-term growth
prospects in all of our businesses." For full-year FY 2014, the Company
anticipates revenues to grow in the range of 6% to 8% YoY and diluted EPS to
be in the range of $4.22 to $4.34. The Full Research Report on Varian Medical
Systems, Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/bd48_VAR]

--

DexCom, Inc. Research Report

On November 1, 2013, DexCom, Inc. (DexCom) announced that the Company's
management will provide an update during its upcoming investor conferences.
DexCom stated that the Company's Executive Vice President of Strategy and
Corporate Development, Steve Pacelli, will present at the Stephens Fall
Investment Conference in New York on November 12, 2013 at 9:00 a.m. EST;
President and Chief Operating Officer Kevin Sayer will present at the 2013
Credit Suisse Healthcare Conference in Scottsdale Arizona on November 13, 2013
at 3:30 p.m. MST; and Terry Greg, CEO of DexCom, will present at the Canaccord
Genuity Medical Technology & Diagnostics Forum in New York on November 14,
2013 at 9:30 a.m. EST. The Company informed that the live webcast of the
conferences will be available on its Investor Relations website. The Full
Research Report on DexCom, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/d377_DXCM]

--

Zeltiq Aesthetics, Inc. Research Report

On October 30, 2013, Zeltiq Aesthetics, Inc. (Zeltiq) reported its Q3 2013
financial results. Net revenue came in at $29.5 million, up 64.4% YoY. Net
loss for the quarter stood at $2.8 million, or $0.08 per share, compared to a
net loss of $5.2 million, or $0.15 per share, in Q3 2012. Mark Foley,
President and CEO of Zeltiq, said "Our outstanding Q3 performance resulted
from a growing leadership position in the market along with the continued
execution of our sales team in the large and underpenetrated non-invasive, fat
reduction market. We had our second highest system placement quarter to-date
and our highest system placement quarter, ever, in our North America market.
Our continued efforts to drive utilization were further evidenced in two new
practice partnering initiatives that we launched in the quarter -
CoolSculpting University and CoolConnect." The Full Research Report on Zeltiq
Aesthetics, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/b15b_ZLTQ]

--

Globus Medical, Inc. Research Report

On October 30, 2013, Globus Medical, Inc. (Globus) reported its Q3 2013
financial results. The Company posted net sales of $107.2 million, up 13.1%
YoY. Net income came in at $20.3 million, or $0.22 per diluted share, compared
with $16.5 million, or $0.18 per diluted share in Q3 2012. David Paul,
Chairman and CEO of Globus, commented, "Our growth this quarter is again
attributable to the increased adoption and success of newer, more disruptive
products, which are designed to provide better treatment for the patient, and
are safer and easier to use for the surgeon, "He continued, " Our excellent
product development execution and robust sales force expansion have us well
positioned to continue to take share in the spine market into 2014 and
beyond." The Company also reiterated revenue guidance of approximately $432
million for full-year 2013. The Full Research Report on Globus Medical, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/5898_GMED]

--

Abaxis, Inc. Research Report

On October 25, 2013, Abaxis, Inc. (Abaxis) announced an R&D agreement with
LamdaGen Corporation (LamdaGen) to integrate LamdaGen's high-sensitivity
Plasmonic ELISA technology on the Abaxis Piccolo and VetScan rotors. Abaxis
informed that system feasibility testing is currently underway. Clint
Severson, CEO of Abaxis said, "We believe that LamdaGen's technology will
provide a unique opportunity for Abaxis to integrate a high sensitivity
immuno-based system onto our existing rotor-based platforms." He added, "If
proven viable, both medical and veterinary customers will be able to
simultaneously analyze for chemistry parameters as well as for infectious
disease, hormones and a wide range of other markers on the same rotor. The
ability to unify both diagnostic systems onto our existing rotor will greatly
expand Abaxis' global diagnostic offerings." The Full Research Report on
Abaxis, Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/ec55_ABAX]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
    are only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.